<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment-related toxicity from the use of radiation therapy for gynecologic malignancies</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment-related toxicity from the use of radiation therapy for gynecologic malignancies</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment-related toxicity from the use of radiation therapy for gynecologic malignancies</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristin A Bradley, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Derek R McHaffie, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arno J Mundt, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Don S Dizon, MD, FACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 14, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H15665224"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Radiation therapy (RT) represents an important therapeutic component in the management of many gynecologic malignancies. Based upon evidence-based treatment guidelines, RT is indicated in up to 60 percent of cervical cancer patients, 45 percent of endometrial cancer patients, 35 percent of vulvar cancer patients, 100 percent of vaginal cancer patients, and 5 percent of patients with ovarian cancer [<a href="#rid1">1,2</a>].</p><p>In this topic, the spectrum of both acute and late side effects associated with RT, specifically as it relates to the treatment of gynecologic malignancies, will be reviewed. An understanding of potential side effects is important for patient management and survivorship issues. An overview of the general principles, modalities, and techniques of RT is found elsewhere. A more detailed discussion of the indications for RT for specific cancer sites and stages can be found in topic reviews for each cancer site. (See  <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">"Radiation therapy techniques in cancer treatment"</a>.)</p><p class="headingAnchor" id="H19481374"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>RT for gynecologic cancers can be employed as primary (definitive) treatment, following surgery (adjuvant), or before surgery (neoadjuvant) in order to reduce the risk of recurrence. For some tumors, RT often is administered with concurrent chemotherapy (chemoradiation) and may incorporate brachytherapy. The normal tissues of the cervix and corpus of the uterus can tolerate high doses of radiation and can recover remarkably well from radiation injury. However, the surrounding normal tissues are more susceptible to radiation injury.</p><p>The incidence and severity of RT side effects depend upon the site, volume of tissue exposed, and treatment schedule, including total dose, dose per fraction, and type of radiation. Modifying factors such as previous surgery, concomitant chemotherapy, and comorbid illness also are influential. At least one large report indicates that smoking history is a strong predictor for both bowel and bladder complications from treatment [<a href="#rid3">3</a>].</p><p>Some patients may be at higher risk for RT-related toxicity. These include patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>Active collagen vascular disease, which is a well-known relative contraindication to radiotherapy [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inflammatory bowel disease (IBD) – Patients with IBD may be at an increased risk of acute and late bowel complications [<a href="#rid5">5</a>], although the data appear to be conflicting, especially when trying to tease out the effects related to RT from those that might be related to the natural history of IBD [<a href="#rid6">6,7</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vascular disorders – Retrospective data suggest that diabetes and hypertension may increase the risk for late toxicity, presumably related to microvascular disease. This includes reports of a greater preponderance of significant bowel complications following definitive radiation for cervix cancer [<a href="#rid8">8,9</a>], although the presence of these conditions was not associated with a greater risk for acute toxicity in at least one report that included women with endometrial cancer [<a href="#rid10">10</a>].</p><p></p><p class="headingAnchor" id="H19481404"><span class="h1">TIMING OF RT-RELATED TOXICITIES</span><span class="headingEndMark"> — </span>Radiation therapy (RT) can be associated with side effects that can occur at any time during treatment or even years later. For purposes of this topic review, we will adopt the following definitions of these toxicities:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute toxicities refer to those with onset during or shortly after the course of treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subacute toxicities are those that initially manifest 4 to 12 weeks after RT has been completed. Most commonly, subacute effects represent prolonged recovery from more significant acute toxicity. Though effects are commonly observed during this period, there are very few distinct radiation injuries that are subacute in onset, such as pneumonitis or myositis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late toxicities are those occurring after three months. These often reflect the spectrum of radiation tissue changes that can be lasting and irreversible. </p><p></p><p class="headingAnchor" id="H15665238"><span class="h1">GENITOURINARY SYSTEM TOXICITIES</span><span class="headingEndMark"> — </span>The impact of RT on the genitourinary (GU) system depends on the dose of RT and the tissue impacted. However, defining dose-response relationships for acute complication risk to the urinary bladder has proven elusive, as volumes are constantly in a state of change [<a href="#rid11">11</a>]. The bladder typically tolerates common adjuvant doses of radiation better than bowel (45 to 50 Gy). For this reason, when administering whole-pelvic radiation, it is common to request that patients come to daily treatment with a full bladder in order to displace bowel from the pelvis. It is important to distinguish complications related to whole-bladder doses versus focal injury from higher radiation doses to partial bladder volumes, more commonly seen when incorporating brachytherapy (BT) as a component of treatment. When BT is employed as a means of dose escalation for definitive, nonoperative management of primary gynecologic malignancies, the risk of GU morbidity is higher, and spectrum of risk is different. </p><p class="headingAnchor" id="H19481440"><span class="h2">Acute radiation cystitis</span><span class="headingEndMark"> — </span>Acute RT-related cystitis can be a common complication with conventionally dosed pelvic RT, although the incidence is highly variable. It can be associated with irritative voiding symptoms (dysuria, frequency, urgency, and nocturia) and bladder spasms. It is due to RT-induced bladder inflammation and edema, which can compromise urothelial integrity. The use of intensity-modulated RT has been shown to reduce patient-reported GU toxicity with adjuvant pelvic treatment following hysterectomy for cervical and endometrial cancer [<a href="#rid12">12,13</a>].</p><p>When they occur during RT, the symptoms typically resolve in one to two weeks after completing therapy. It is important, however, that other etiologies, such as a superimposed urinary tract infection, be ruled out.</p><p>Treatment depends upon the nature of symptoms, and conservative management is often appropriate. The effectiveness of medical therapy during the acute period is largely anecdotal. Since acute bladder effects are most commonly grade 1 or 2 and transient, there are minimal data on the comparative effectiveness of medical treatment. Some commonly employed strategies we utilize include: </p><p class="bulletIndent1"><span class="glyph">●</span>Non-steroidal anti-inflammatory drugs for patients who complain of irritative voiding symptoms </p><p class="bulletIndent1"><span class="glyph">●</span>Anticholinergics and/or antispasmodics (eg, <a class="drug drug_general" data-topicid="9728" href="/z/d/drug information/9728.html" rel="external">oxybutynin</a> or <a class="drug drug_general" data-topicid="8545" href="/z/d/drug information/8545.html" rel="external">hyoscyamine</a>) for cystitis or bladder spasm</p><p class="bulletIndent1"><span class="glyph">●</span>Cranberry juice or <a class="drug drug_general" data-topicid="9761" href="/z/d/drug information/9761.html" rel="external">phenazopyridine</a> for dysuria. Generally use of phenazopyridine is limited to two to three weeks when acute cystitis symptoms are at their worst.</p><p></p><p class="headingAnchor" id="H19481486"><span class="h2">Late signs and symptoms</span><span class="headingEndMark"> — </span>Late GU toxicities generally arise as a result of RT-induced epithelial and microvascular changes, which can lead to changes in bladder physiology. These changes are often permanent and are largely mediated by fibrosis via collagen deposition within the epithelium and muscularis, resulting in diminished bladder capacity and loss of tissue compliance. Though the pathophysiology differs, late bladder effects can result in a similar spectrum of lower urinary tract symptoms to that seen in the acute phase, such as urgency and frequency. This is often attributed to bladder overactivity or contraction. With significant contraction, bladder dysfunction can result in urge incontinence. </p><p>At expected doses of external-beam RT employed for gynecologic cancers (40 to 50 Gy), the likelihood of serious lasting side effects is low [<a href="#rid14">14</a>]. Five-year follow-up of the Post-Operative Radiation Therapy in Endometrial Carcinoma 1 (PORTEC-1) trial randomizing 46 Gy adjuvant pelvic radiation and observation in patients with endometrial cancer observed no serious (grade 3 or 4) late GU toxicity in the radiotherapy arm [<a href="#rid15">15</a>]. There was a 5 percent absolute increase in reported grade 1 or 2 GU late effects attributed to radiotherapy [<a href="#rid15">15</a>]. Long-term quality of life analyses indicate that measurable differences persist at 15 years with regards to urinary function, specifically rates of urinary urgency, incontinence, and limitations in daily activities due to bladder symptoms [<a href="#rid16">16</a>].</p><p>Higher total doses of radiation can be associated with focal injury and lead to a risk of hematuria or ulceration. Persistent non-healing can result in stone formation. Contracture can produce pain syndromes. Ureteral stricture is uncommon without tumor involvement at presentation. Urethrovaginal and vesicovaginal fistula are also seen on occasion from focal, high-dose radiation injury. Fistula risk is also heavily influenced by direct tumor invasion of GU structures before therapy. In the definitive management of cervix cancer, where the incorporation of BT is considered standard of care, the probability of late grade 3 or 4 GU toxicity is &lt;3 percent [<a href="#rid17">17</a>]. Modern series that incorporate three-dimensional treatment planning information into BT suggest that the risk for these late side effects correlates best with the maximum dose received by 2 cc of normal bladder (D2cc). The complication probability for a total equivalent dose of 101 Gy is approximately 10 percent, with newer analyses recommending a bladder dose D2cc constraint of 80 to 85 Gy in the absence of bladder involvement by tumor [<a href="#rid18">18-20</a>].</p><p>The timing of onset is typically one to three years after treatment, though much longer latencies have been described, particularly with the higher total doses of radiation associated with cervix cancer treatment [<a href="#rid21">21</a>]. Mild effects can be difficult to distinguish from the effects of aging or prior pelvic surgery. Obesity appears to increase the likelihood of serious complications [<a href="#rid3">3</a>]. In patients with a history of pelvic radiation, hemorrhagic cystitis can develop years down the road. Refractory cases are frequently complicated by the ongoing need for anticoagulation for comorbid illness. The preferred management is not well defined. Conservative management is preferred, as intervention can precipitate high-grade toxicity. Sodium <a class="drug drug_general" data-topicid="9755" href="/z/d/drug information/9755.html" rel="external">pentosan polysulfate</a> has been used for radiation-related hematuria with resolution of symptoms [<a href="#rid22">22</a>]. Cautery, intravesicular formalin, and argon plasma coagulation have also been described. High rates of symptomatic improvement have also been reported for hyperbaric oxygen when used to treat symptomatic late radiation cystitis [<a href="#rid23">23,24</a>]. </p><p class="headingAnchor" id="H15665245"><span class="h1">GASTROINTESTINAL</span><span class="headingEndMark"> — </span>Gastrointestinal (GI) toxicity is the most common source of both acute and late side effects from pelvic radiation, and the most likely to result in a measurable decline across multiple quality of life domains such as limitation of daily activities and impaired social function [<a href="#rid25">25</a>]. Both small and large intestines are susceptible to RT-related toxicity in the management of gynecologic cancers. The high proliferative rate of small bowel epithelium makes it more vulnerable to the acute effects of radiation than most other tissues. Following hysterectomy, much of the bowel comes to rest deeper in the pelvis, often accompanied by adhesions. The rectum is a common site for late injury, particularly when dose escalation is a component of management.</p><p class="headingAnchor" id="H114044419"><span class="h2">Acute radiation injury</span><span class="headingEndMark"> — </span>The small bowel is very sensitive to the early effects of RT, and when it is contained within the RT field, radiation injury can present acutely as nausea and vomiting. This can be followed by the onset of diarrhea and abdominal cramping two to three weeks into a course of RT. This latency is believed to be due to accumulated damage and loss of normal crypt epithelium. Symptoms develop as a result of insufficient replacement of villus epithelium despite compensatory proliferation, resulting in inflammation and a compromised mucosal barrier [<a href="#rid26">26</a>]. In general, the symptoms of bowel wall mucosal injury can include cramping, diarrhea, anorexia, malaise, rectal discomfort, and tenesmus. The risk for bowel toxicity is a function of both total dose and volume irradiated. Based on findings from the Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) project, it appears that limiting the volume of small bowel receiving &gt;45 Gy correlates with a reduction in the risk of acute grade &gt;3 GI toxicity. However, whether these dose-volume constraints will translate to reduced late toxicity has not yet been established [<a href="#rid27">27</a>]. At least one trial suggests that the degree of acute toxicity does predict for the development of late effects.</p><p>Acute radiation injury of the large bowel can be difficult to distinguish from changes attributed to the small bowel, as both can result in loose stool and cramping. Injury to the small bowel commonly leads to high-volume, watery diarrhea. Acute effects on large bowel can produce fecal urgency, clustered bowel movements, and tenesmus. Bowel obstruction, ileus, and GI bleeding are not characteristic of acute enteropathy, but can be seen as late toxicity. </p><p>For a standard adjuvant course of radiation (45 to 50 Gy) using conventional 3D conformal techniques, approximately 50 percent of patients will experience changes in bowel function in the acute setting. The likelihood for acute grade 3 GI side effects is around 3 percent [<a href="#rid28">28,29</a>]. The rate of grade &gt;3 GI effects increases to approximately 20 percent in the definitive management of cervix cancer with combination <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and dose escalation via brachytherapy (BT) [<a href="#rid17">17</a>]. This includes a 10 percent risk for grade 3 nausea and vomiting, which is uncommon with radiation alone.</p><p>In the era of combined chemoradiation, the largest difference in potential treatment toxicities compared with radiation alone is gastrointestinal. The concurrent use of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> with pelvic radiation more than doubles the risk for grade ≥3 acute GI side effects [<a href="#rid30">30</a>]. </p><p>Incorporating newer treatment techniques, such as intensity-modulated RT (IMRT), can minimize the amount of radiation received by normal bowel. Multiple single-arm studies pointed to a reduction in the probability of GI side effects with intensity-modulated pelvic radiation, which has been confirmed in randomized phase III trials [<a href="#rid12">12,13,31-34</a>]. When compared with standard four-field radiation, IMRT reduces patient-reported GI toxicity, reduces the need for anti-diarrheal medication, and improves quality of life in the acute setting [<a href="#rid12">12,13</a>].</p><p>The treatment of acute radiation injury is largely symptomatic:</p><p class="bulletIndent1"><span class="glyph">●</span>Proctitis and rectal discomfort often respond to small enemas with <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> or cod liver oil, anti-inflammatory suppositories, and a low-residue diet with no grease, spices, or insoluble fiber. Two small prospective studies demonstrate a benefit for topical sodium butyrate enemas in the treatment of acute radiation proctitis [<a href="#rid35">35,36</a>]. Butyrate is a short chain fatty acid, the preferred nutritional source for the colonic epithelium. </p><p></p><p>For the prevention of radiation proctitis, the Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO) recommend probiotics, based on clinical trial results in colorectal cancer patients and those with pelvic malignancies [<a href="#rid37">37</a>]. Although the MASCC/ISOO also recommended intravenous <a class="drug drug_general" data-topicid="8533" href="/z/d/drug information/8533.html" rel="external">amifostine</a> for the prevention of radiation proctitis [<a href="#rid38">38</a>], supporting evidence comes largely from small studies in patients receiving radiotherapy for rectal cancer, without evidence of benefit in patients with other pelvic malignancies [<a href="#rid39">39</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">Ondansetron</a> has been shown to reduce radiotherapy-induced nausea and vomiting [<a href="#rid40">40</a>]. At least one randomized trial supports its superiority to the combination of <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a> and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid41">41</a>]. The addition of dexamethasone to ondansetron appears to improve nausea control [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antidiarrheal medications are used symptomatically for enteritis and are safe in the acute setting. There are minimal data by which to refine treatment decisions. We typically initiate <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> as a first measure. When symptoms are refractory, <a class="drug drug_general" data-topicid="9370" href="/z/d/drug information/9370.html" rel="external">diphenoxylate-atropine</a> and <a class="drug drug_general" data-topicid="9721" href="/z/d/drug information/9721.html" rel="external">tincture of opium</a> can be effective. A randomized trial shows that <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> is more effective at controlling acute radiation-induced diarrhea than diphenoxylate-atropine [<a href="#rid43">43</a>]. With loperamide-refractory diarrhea, a smaller pilot study showed that subcutaneous octreotide led to complete resolution for 80 percent of patients, with a mean time to response of 2.7 days [<a href="#rid44">44</a>]. The MASCC/ISOO also recommends oral <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> to prevent radiation-induced enteropathy [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many agents have been tested for the prevention of acute effects. These include <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a>, <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">sucralfate</a>, mesalazine, and <a class="drug drug_general" data-topicid="8747" href="/z/d/drug information/8747.html" rel="external">glutamine</a>, but each has failed to show a reduction in GI toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with cervical or endometrial cancer undergoing RT and who are selenium-deficient (whole-blood <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a> concentration &lt;84 microg/L), a phase III trial showed that selenium repletion may be associated with reduced rates of grade 2 or higher diarrhea [<a href="#rid45">45</a>]. However, independent confirmation and validation of these results is needed before this approach can be considered standard.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of probiotics has been studied as a preventive strategy for radiation enteritis. A meta-analysis of six randomized controlled trials demonstrated a lower incidence of radiation-induced diarrhea compared with placebo; however, there was no statistically significant difference in the antidiarrheal medication use or Bristol scale on stool form [<a href="#rid46">46</a>].</p><p></p><p class="headingAnchor" id="H114044456"><span class="h2">Late GI toxicity</span><span class="headingEndMark"> — </span>Although normal small bowel motion is believed to reduce the risk of delayed toxicity, the small bowel is still at risk for late side effects. While the acute gastrointestinal (GI) symptoms of radiation typically resolve within two to four weeks after the completion of treatment, they can become more chronic issues. In most cases, there is a latency of six months to several years until late bowel complications are observed. The pathophysiology of chronic enteropathy is complex and can be related to radiation changes involving multiple tissues and cellular functions. Mucosal atrophy and loss of mucin-producing goblet cells can lead to chronic diarrhea and malabsorption. Fibrosis of the intestinal wall can lead to dysmotility (chronic) and risk for obstruction (acute presentation). </p><p>A small, randomized trial has shown a reduction in grade &gt;2 late GI side effects with IMRT (13.6 versus 50 percent) in the treatment of locally advanced cervical cancer [<a href="#rid47">47</a>]. Another randomized controlled trial in the postoperative setting for cervical cancer demonstrated a reduction in late grade 2 or greater bowel toxicity with IMRT, with the greatest benefit seen in patients also receiving chemotherapy [<a href="#rid34">34</a>].</p><p>The symptoms of late GI toxicity include: </p><p class="bulletIndent1"><span class="glyph">●</span>Chronic diarrhea – When present symptoms may be best managed by a multidisciplinary team to include gastroenterology. Ongoing antidiarrheal medications are often necessary.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malabsorption – This can be related to RT involving the distal ileum. For example, vitamin B12 deficiency after irradiation for cervical cancer occurs in 12 to 20 percent. This usually develops over a period of several years and commonly requires replacement [<a href="#rid48">48-50</a>]. <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">Cholestyramine</a> may be helpful when bile salt malabsorption is present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent bouts of ileus or obstruction. This is best managed conservatively when possible, but commonly requires surgery with resection and anastomosis. Prolonged chronic radiation enteritis can lead to malnutrition, and as such, perioperative nutritional therapy may be an important intervention. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Proliferative mucosal telangiectasias or ulcerations – The development of mucosal telangiectasias and/or ulcerations is related to vascular sclerosis and is most commonly observed in the rectosigmoid colon (radiation-induced proctopathy). The signs can include painless hematochezia, tenesmus, or pain. In addition, characteristic changes of mucosal pallor and proliferative telangiectasias often are seen on the anterior rectal wall on endoscopic evaluation in asymptomatic patients. When present, the median time to onset is 14 months and symptoms typically appear within three years [<a href="#rid51">51</a>]. Most commonly, this late GI toxicity is seen in dose escalation and overall is an uncommon late effect, with a reported incidence of less than 10 percent in a trial performed by the Radiation Therapy Oncology Group (RTOG 90-01) [<a href="#rid52">52</a>]. Recent experience suggests that image-guided BT has the potential to further reduce its incidence [<a href="#rid53">53</a>]. Results from the prospective EMBRACE study of magnetic resonance imaging-guided adaptive BT reported that a rectal D<sub>2cm3</sub> &lt;65 Gy was associated with one-half the risk of proctitis compared with a D<sub>2cm3</sub> ≥65 Gy [<a href="#rid54">54</a>]. For patients with such symptoms, a colonoscopy is required to exclude malignancy or other pathology. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with rectal proctopathy, conservative management is often appropriate. Avoiding constipation may limit episodes of bleeding. Medical therapy includes <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">sucralfate</a> enemas [<a href="#rid38">38</a>], an aluminum hydroxide complex that binds and protects injured mucosa [<a href="#rid55">55,56</a>]. Guidelines from the MASCC and ISOO suggest that hyperbaric oxygen may be helpful in the management of radiation proctitis [<a href="#rid38">38</a>], although data are mixed [<a href="#rid57">57,58</a>]. In our experience, hyperbaric oxygen may reduce bleeding in refractory cases of late radiation proctitis. Additionally, in refractory cases, endoscopic intervention can control bleeding with a high likelihood of durable response [<a href="#rid59">59,60</a>]. One study indicates that topical formalin is as effective as argon plasma coagulation at controlling bleeding [<a href="#rid60">60</a>]. Unlike acute proctitis, topical butyrate does not reduce symptoms of chronic proctitis [<a href="#rid61">61</a>]. Surgical management is reserved for intractable cases, such as transfusion-dependent bleeding, refractory pain, and fistula, although it is rarely indicated.</p><p></p><p class="headingAnchor" id="H15665252"><span class="h1">VAGINA</span><span class="headingEndMark"> — </span>Vaginal toxicity is common for women undergoing treatment for cervical and uterine cancer, in which pelvic RT and/or brachytherapy (BT) is often administered. This can lead to sexual dysfunction and interfere with quality of life. As with each organ system reviewed in this topic, the highest incidence rates for vaginal toxicity are seen in the definitive management of locally advanced cervix cancer, where over half of women report sexual dysfunction [<a href="#rid62">62</a>]. Significant vaginal toxicity is much less likely with standard adjuvant therapy. One large institutional series reported no grade &gt;2 vaginal toxicity with high-dose rate BT alone to the vaginal cuff in the treatment of endometrial cancer [<a href="#rid63">63</a>]. Similarly, vaginal toxicity was 1 percent, none severe, in a randomized trial assessing pelvic radiation versus observation [<a href="#rid64">64</a>]. In long-term follow-up of this trial, there was no difference in sexual quality of life metrics at 15 years observed in a post-menopausal population [<a href="#rid16">16</a>]. Common toxicities are discussed below.</p><p class="headingAnchor" id="H114044712"><span class="h2">Acute vaginal mucositis</span><span class="headingEndMark"> — </span>Acutely, women can experience vaginal mucositis during or following pelvic RT, although the incidence is not well documented because large prospective trials have not consistently reported rates of vaginal toxicity. The pathogenesis is similar to RT-induced changes observed at other mucosal surfaces. Clinically, vaginal changes range from erythema to superficial ulceration, which may be associated with exudative changes, serous discharge, and a predisposition to infection.</p><p>We approach vaginal mucositis with a multi-tiered approach consisting of vulvar cleansing with mild soap or Sitz bathes to remove topical irritants, such as urine. Vaginal douches (eg, diluted <a class="drug drug_general" data-topicid="113931" href="/z/d/drug information/113931.html" rel="external">hydrogen peroxide</a> and water or the local anesthetic and anti-inflammatory agent, <a class="drug drug_general" data-topicid="8682" href="/z/d/drug information/8682.html" rel="external">benzydamine</a>) and local vaginal estrogen can improve symptoms. One systematic review consisting of both randomized trials and observational studies suggested that douches were effective therapeutic aides [<a href="#rid65">65</a>]. At this time, benzydamine is available only outside of the United States.</p><p class="headingAnchor" id="H114044751"><span class="h2">Vaginal ulceration or necrosis</span><span class="headingEndMark"> — </span>Full thickness vaginal ulceration and necrosis are uncommon signs after RT, but when present, are often seen in women requiring interstitial BT for vaginal cancers [<a href="#rid66">66</a>]. Necrosis results from loss of progenitor cells in the mucosal basal layer, leading to delayed healing that can extend beyond three months. It has been observed that the proximal vagina has a greater radiation tolerance. The majority of serious complications, such as necrosis, occur in the distal vagina.  </p><p>Initial management is conservative. Douches, such as dilute <a class="drug drug_general" data-topicid="113931" href="/z/d/drug information/113931.html" rel="external">hydrogen peroxide</a>, should be used for cleansing. Patients should be monitored for signs of acute infection. Common strategies for persistent non-healing include <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> or hyperbaric oxygen, both of which are supported by small observational studies that show high rates of resolution of necrosis [<a href="#rid67">67-69</a>]. However, well-conducted prospective trials are needed in this area. </p><p class="headingAnchor" id="H114044765"><span class="h2">Vaginal stenosis</span><span class="headingEndMark"> — </span>Stenosis is the most common late vaginal side effect, and it can be seen following pelvic radiation and/or BT. As a result of the subsequent shortening of vaginal length, pain with penetration (or vaginismus) is a frequent complaint, which is likely as a result of circumferential narrowing of the vaginal vault or the development of adhesions with the vagina. This can also interfere with the need for ongoing surveillance pelvic exams. At its most extreme, the vault can become obliterated due to agglutination of the vaginal walls. </p><p>Due to significant heterogeneity between patient populations, methods, endpoints, and older RT techniques, it is difficult to define the incidence of this complication. Perhaps the biggest risk of vaginal stenosis is the combined treatment of pelvic RT plus BT. A publication from the EMBRACE study investigators suggests planning goals for pelvic external-beam RT and image-guided BT to reduce the risk for vaginal stenosis [<a href="#rid70">70</a>]. Patient-reported outcomes suggest that sexual dysfunction as a consequence of vaginal morbidity is underreported [<a href="#rid71">71</a>]. When not contraindicated, an older randomized study shows that topical estrogen (one to three times weekly) applied in the first six months following radiation reduces dyspareunia and improves vaginal caliber [<a href="#rid72">72</a>]. When observed, this typically begins three to six months after therapy. This is often accompanied by mucosal pallor and telangiectasia on pelvic exam.</p><p>The primary treatment for stenosis is the application of vaginal dilators, which are available in grades of both length and width. However, while many guidelines support their use as both prevention and treatment for post-radiation vaginal stenosis, additional data on their efficacy are needed [<a href="#rid73">73</a>]. Two case series and a comparative study using historical controls suggest that dilation might be associated with a longer vaginal length [<a href="#rid74">74,75</a>], but at least two small randomized trials from one institution showed no improvement in sexual scores or global sexual health in women who were encouraged to practice dilation [<a href="#rid76">76</a>]. In addition, topical <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">mitomycin</a> may have a role, although the data are mostly evaluating it to prevent stenosis [<a href="#rid77">77,78</a>].</p><p class="headingAnchor" id="H114044771"><span class="h2">Fistulas</span><span class="headingEndMark"> — </span>Rectovaginal and vesicovaginal fistulas are a rare, but a very serious potential complication of treatment. They are seen almost exclusively following the need for high-dose radiation to control gross disease involving the vagina or when tumor has invaded adjacent organs, such as bladder or rectosigmoid. The need for interstitial BT may increase this risk compared with intracavitary BT. Risk factors for fistula development include tumor invasion of the bladder or rectum and the development of necrosis following treatment [<a href="#rid79">79</a>]. When possible, persistent non-healing should be managed conservatively, as biopsy and surgical management can precipitate fistula development. As with vaginal necrosis, hyperbaric oxygen and <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> can be used. </p><p class="headingAnchor" id="H15665258"><span class="h1">OVARIES</span><span class="headingEndMark"> — </span>Radiation to the ovaries may lead to infertility or premature menopause. In general, the ovaries are very sensitive to even low total doses of radiation and small fraction sizes, with oocytes being more sensitive than granulosa or thecal cells. At doses required for the management of adult malignancies, premature ovarian failure (POF) is the expected result when the ovaries remain within the radiation field. Sensitivity is age-dependent and observed to increase with advancing age. The dose predicted to result in POF immediately following treatment is 16.5 Gy at 20 years old and 14.3 Gy at 30 years old [<a href="#rid80">80</a>]. With lower-dose exposures (most commonly seen in pediatric malignancies), total-body irradiation, or internal scatter from an adjacent radiation field, estrogen levels can recover between 6 and 18 months. However, early menopause is still likely to occur. The dose necessary to eliminate 50 percent of remaining oocytes has been determined to be between 2 and 4 Gy [<a href="#rid81">81</a>].</p><p>In premenopausal women &lt;40 years old, laparoscopic ovarian transposition may be employed before a course of pelvic radiation. Understanding of the indicated radiation field by the surgeon is necessary to enhance the probability of preservation, as it is desirable for the transposed ovary to be at least 3 cm from the radiation field border. Often, clips are used to allow the radiation oncologist to identify the ovaries' new location. High rates of preservation (80 to 88 percent) have been reported, with an improved likelihood of success when both ovaries are transposed [<a href="#rid82">82,83</a>].</p><p>It is important that transposition only be considered in patients considered at low risk for spread to the ovary. Metastases occurring within a transposed ovary have been described in the management of cervical cancer, with greater risk for adenocarcinomas than squamous cell carcinomas [<a href="#rid84">84</a>]. </p><p>Hormone replacement therapy (for patients who do not undergo ovarian transposition) is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3246.html" rel="external">"Management of early-stage cervical cancer", section on 'Hormone replacement therapy for menopausal symptoms'</a>.)</p><p class="headingAnchor" id="H15665265"><span class="h1">BONE AND BONE MARROW</span><span class="headingEndMark"> — </span>Radiation does not typically result in acute injury to healthy bone. The side effects of radiation on mature bone are related to metabolic changes that can lead to skeletal consequences after a latency of several years. Pelvic radiation can increase the risk for pelvic or sacral insufficiency fractures [<a href="#rid85">85-87</a>]. Endothelial damage and intimal fibrosis can lead to reduced blood flow to healthy bone. Osteoblast proliferation is affected by radiation. This results in diminished synthesis of bone matrix, leading to unbalanced resorptive processes. The result can be the development of focal osteopenia in the radiation field that can be more vulnerable to fracture, particularly at weight-bearing sites.</p><p>Pelvic insufficiency fractures (PIF) are most commonly seen near the sacroiliac joints. The use of modern magnetic resonance imaging (MRI) has led to an increase in the discovery of clinically occult, asymptomatic fractures. The observed risk factors for the development of PIF include older age, preexisting osteopenia, diabetes mellitus, corticosteroid use, low body weight, and radiation dose &gt;50 Gy [<a href="#rid88">88-90</a>].</p><p>More conformal techniques appear to reduce the risk. A systematic review and meta-analysis identified the five-year actuarial incidence of PIF at 15 percent following pelvic radiation, of which 59 percent were symptomatic. In studies using modern radiotherapy, such as intensity-modulated RT, the incidence was lower, at 4.8 percent [<a href="#rid90">90</a>].</p><p>Most acute grade 4 complications during chemoradiation are hematologic [<a href="#rid91">91</a>]. Hematopoietic cells are sensitive to low doses of radiation. It is estimated that up to 25 percent of bone marrow reserves are located in the bones of the pelvis. Intensity-modulated RT can be used to minimize the dose of radiation to pelvic marrow. Several studies suggest that this lowers the risk for hematologic complications and may improve the likelihood of completing all intended doses of chemotherapy [<a href="#rid92">92-94</a>].</p><p>Radiation-induced lumbosacral plexopathy has been described as a rare consequence of pelvic radiation when incorporating brachytherapy for dose escalation [<a href="#rid95">95</a>]. When observed, the risk is associated with doses that are non-standard and avoidable with modern techniques (&gt;70 Gy). At standard adjuvant doses, this risk is negligible.</p><p class="headingAnchor" id="H15665272"><span class="h1">SKIN</span><span class="headingEndMark"> — </span>Acute skin reactions range from erythema and soreness to moist desquamation, and on rare occasion, ulceration. High-energy photons (10 to 18 Mv) and multi-field arrangements are typically used with pelvic RT. Both of these factors have a skin-sparing effect on the distribution of radiation dose. As a result, any observed radiation dermatitis for treatment of gynecologic malignancies is typically mild. </p><p>The major exception is vulvar cancer, where grade 3 skin reactions are common, or any situation in which the inguinal nodes are included for treatment. The advent of intensity-modulated RT for vulvar cancer has improved the ability to minimize skin doses outside of the target volume, such as the perianal region.</p><p>Skin erythema or dry desquamation can be treated with skin hygiene, water-based creams, or ointments such as <a class="drug drug_general" data-topicid="101844" href="/z/d/drug information/101844.html" rel="external">lanolin</a>. Topical anesthetics can help manage discomfort. Moist desquamation can be managed with Silvadene cream until healing is complete. Dermatitis typically resolves gradually in one to three weeks. The late spectrum of potential soft tissue effects includes persistent hyperpigmentation, telangiectasia, and fibrosis. In addition, radiation-induced fibrosis may respond to oral <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> and alpha-tocopherol (<a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a>) [<a href="#rid96">96</a>].</p><p class="headingAnchor" id="H2089808297"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Radiation therapy (RT) represents an important therapeutic component in the management of many gynecologic malignancies. Therefore, an understanding of potential side effects is important for patient management and survivorship issues. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients with a gynecologic cancer may be at higher risk for RT-related toxicity. These include patients with active collagen vascular disease, inflammatory bowel disease (IBD), and vascular disorders (including diabetes and hypertension). (See <a class="local">'Overview'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RT can be associated with side effects that can occur at any time during treatment or even years later. (See <a class="local">'Timing of RT-related toxicities'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute toxicities refer to those with onset during or shortly after the course of treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Subacute toxicities are those that initially manifest 4 to 12 weeks after RT has been completed. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Late toxicities are those occurring after three months. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute RT-related cystitis can be a common complication with conventionally dosed pelvic RT, although the incidence is highly variable. It can be associated with irritative voiding symptoms (dysuria, frequency, urgency, and nocturia) and bladder spasms. It is due to RT-induced bladder inflammation and edema, which can compromise urothelial integrity. When they occur during RT, the symptoms typically resolve in one to two weeks after completing therapy. (See <a class="local">'Acute radiation cystitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late GU toxicities generally arise as a result of RT-induced epithelial and microvascular changes, which can lead to changes in bladder physiology. These can result in a similar spectrum of lower urinary tract symptoms to that seen in the acute phase, such as urgency and frequency, which is often attributed to bladder overactivity or contraction. With significant contraction, bladder dysfunction can result in urge incontinence. However, at expected doses of external-beam RT employed for gynecologic cancers (40 to 50 Gy), the likelihood of serious lasting side effects is low. (See <a class="local">'Late signs and symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The small bowel is very sensitive to the early effects of RT, and when it is contained within the RT field, radiation injury can present acutely as nausea, vomiting, and diarrhea. However, the treatment of acute radiation injury is largely symptomatic. Probiotics during radiation may be useful as a preventative strategy. (See <a class="local">'Acute radiation injury'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The symptoms of late GI toxicity include chronic diarrhea, malabsorption, recurrent bouts of ileus or obstruction, and the development of mucosal telangiectasias or ulcerations. Advances in radiation techniques, including use of intensity-modulated RT and image-guided brachytherapy (BT), have resulted in a reduction in the incidence and severity of late GI toxicity. (See <a class="local">'Late GI toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vaginal toxicity is common for women undergoing treatment for cervical and uterine cancer, in which cases, either pelvic RT or vaginal BT is often administered. This can lead to sexual dysfunction and interfere with quality of life. (See <a class="local">'Vagina'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiation to the ovaries may lead to infertility or premature menopause. The dose necessary to eliminate 50 percent of remaining oocytes has been determined to be between 2 and 4 Gy [<a href="#rid81">81</a>]. Due to these risks, for women who are premenopausal and aged &lt;40 years old, laparoscopic ovarian transposition is often employed before a course of pelvic radiation. (See <a class="local">'Ovaries'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute skin reactions range from erythema and soreness to moist desquamation, and on rare occasion, ulceration. High-energy photons (10 to 18 Mv) and multi-field arrangements are typically used with pelvic radiotherapy. Both of these factors have a skin-sparing effect on the distribution of radiation dose. As a result, any observed radiation dermatitis for treatment of gynecologic malignancies is typically mild. The major exception is vulvar cancer, where grade 3 skin reactions are common, or any situation in which the inguinal nodes are included for treatment. (See <a class="local">'Skin'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part II--carcinoma of the endometrium. Cancer 2004; 101:682.</a></li><li><a class="nounderline abstract_t">Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part I--malignancies of the cervix, ovary, vagina and vulva. Cancer 2004; 101:671.</a></li><li><a class="nounderline abstract_t">Eifel PJ, Jhingran A, Bodurka DC, et al. Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer. J Clin Oncol 2002; 20:3651.</a></li><li><a class="nounderline abstract_t">Wo J, Taghian A. Radiotherapy in setting of collagen vascular disease. Int J Radiat Oncol Biol Phys 2007; 69:1347.</a></li><li><a class="nounderline abstract_t">Willett CG, Ooi CJ, Zietman AL, et al. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. Int J Radiat Oncol Biol Phys 2000; 46:995.</a></li><li><a class="nounderline abstract_t">Green S, Stock RG, Greenstein AJ. Rectal cancer and inflammatory bowel disease: natural history and implications for radiation therapy. Int J Radiat Oncol Biol Phys 1999; 44:835.</a></li><li><a class="nounderline abstract_t">Song DY, Lawrie WT, Abrams RA, et al. Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys 2001; 51:455.</a></li><li><a class="nounderline abstract_t">Maruyama Y, Van Nagell JR Jr, Utley J, et al. Radiation and small bowel complications in cervical carcinoma therapy. Radiology 1974; 112:699.</a></li><li><a class="nounderline abstract_t">van Nagell JR Jr, Parker JC Jr, Maruyama Y, et al. Bladder or rectal injury following radiation therapy for cervical cancer. Am J Obstet Gynecol 1974; 119:727.</a></li><li><a class="nounderline abstract_t">Jereczek-Fossa BA, Badzio A, Jassem J. Factors determining acute normal tissue reactions during postoperative radiotherapy in endometrial cancer: analysis of 317 consecutive cases. Radiother Oncol 2003; 68:33.</a></li><li><a class="nounderline abstract_t">Viswanathan AN, Yorke ED, Marks LB, et al. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys 2010; 76:S116.</a></li><li><a class="nounderline abstract_t">Klopp AH, Yeung AR, Deshmukh S, et al. Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203. J Clin Oncol 2018; 36:2538.</a></li><li><a class="nounderline abstract_t">Yeung AR, Pugh SL, Klopp AH, et al. Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study. J Clin Oncol 2020; 38:1685.</a></li><li><a class="nounderline abstract_t">Marks LB, Carroll PR, Dugan TC, Anscher MS. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 1995; 31:1257.</a></li><li><a class="nounderline abstract_t">King LS. Editorial: The humanization of medicine. JAMA 1975; 231:738.</a></li><li><a class="nounderline abstract_t">Nout RA, van de Poll-Franse LV, Lybeert ML, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol 2011; 29:1692.</a></li><li><a class="nounderline abstract_t">Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340:1137.</a></li><li><a class="nounderline abstract_t">Georg P, Pötter R, Georg D, et al. Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy. Int J Radiat Oncol Biol Phys 2012; 82:653.</a></li><li><a class="nounderline abstract_t">Tanderup K, Nesvacil N, Kirchheiner K, et al. Evidence-Based Dose Planning Aims and Dose Prescription in Image-Guided Brachytherapy Combined With Radiochemotherapy in Locally Advanced Cervical Cancer. Semin Radiat Oncol 2020; 30:311.</a></li><li><a class="nounderline abstract_t">Manea E, Escande A, Bockel S, et al. Risk of Late Urinary Complications Following Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: Refining Bladder Dose-Volume Parameters. Int J Radiat Oncol Biol Phys 2018; 101:411.</a></li><li><a class="nounderline abstract_t">Perez CA, Breaux S, Bedwinek JM, et al. Radiation therapy alone in the treatment of carcinoma of the uterine cervix. II. Analysis of complications. Cancer 1984; 54:235.</a></li><li><a class="nounderline abstract_t">Sandhu SS, Goldstraw M, Woodhouse CR. The management of haemorrhagic cystitis with sodium pentosan polysulphate. BJU Int 2004; 94:845.</a></li><li><a class="nounderline abstract_t">Oscarsson N, Arnell P, Lodding P, et al. Hyperbaric oxygen treatment in radiation-induced cystitis and proctitis: a prospective cohort study on patient-perceived quality of recovery. Int J Radiat Oncol Biol Phys 2013; 87:670.</a></li><li><a class="nounderline abstract_t">Oscarsson N, Müller B, Rosén A, et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial. Lancet Oncol 2019; 20:1602.</a></li><li><a class="nounderline abstract_t">Nout RA, Putter H, Jürgenliemk-Schulz IM, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 2009; 27:3547.</a></li><li><a class="nounderline abstract_t">Carr KE. Effects of radiation damage on intestinal morphology. Int Rev Cytol 2001; 208:1.</a></li><li><a class="nounderline abstract_t">Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys 2010; 76:S101.</a></li><li><a class="nounderline abstract_t">Creutzberg CL, van Putten WL, Koper PC, et al. The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. Int J Radiat Oncol Biol Phys 2001; 51:1246.</a></li><li><a class="nounderline abstract_t">Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010; 375:816.</a></li><li><a class="nounderline abstract_t">Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340:1154.</a></li><li><a class="nounderline abstract_t">Chen MF, Tseng CJ, Tseng CC, et al. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 2007; 67:1438.</a></li><li><a class="nounderline abstract_t">Folkert MR, Shih KK, Abu-Rustum NR, et al. Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer. Gynecol Oncol 2013; 128:288.</a></li><li><a class="nounderline abstract_t">Barillot I, Tavernier E, Peignaux K, et al. Impact of post operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: results of the phase II RTCMIENDOMETRE French multicentre trial. Radiother Oncol 2014; 111:138.</a></li><li><a class="nounderline abstract_t">Chopra S, Gupta S, Kannan S, et al. Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial. J Clin Oncol 2021; 39:3682.</a></li><li><a class="nounderline abstract_t">Vernia P, Fracasso PL, Casale V, et al. Topical butyrate for acute radiation proctitis: randomised, crossover trial. Lancet 2000; 356:1232.</a></li><li><a class="nounderline abstract_t">Hille A, Herrmann MK, Kertesz T, et al. Sodium butyrate enemas in the treatment of acute radiation-induced proctitis in patients with prostate cancer and the impact on late proctitis. A prospective evaluation. Strahlenther Onkol 2008; 184:686.</a></li><li><a class="nounderline abstract_t">Bowen JM, Gibson RJ, Coller JK, et al. Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. Support Care Cancer 2019; 27:4011.</a></li><li><a class="nounderline abstract_t">Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2020; 126:4423.</a></li><li><a class="nounderline abstract_t">Bensadoun RJ, Schubert MM, Lalla RV, Keefe D. Amifostine in the management of radiation-induced and chemo-induced mucositis. Support Care Cancer 2006; 14:566.</a></li><li><a class="nounderline abstract_t">Feyer PCh, Maranzano E, Molassiotis A, et al. Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. Support Care Cancer 2005; 13:122.</a></li><li><a class="nounderline abstract_t">Sykes AJ, Kiltie AE, Stewart AL. Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. Support Care Cancer 1997; 5:500.</a></li><li><a class="nounderline abstract_t">National Cancer Institute of Canada Clinical Trials Group (SC19), Wong RK, Paul N, et al. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol 2006; 24:3458.</a></li><li><a class="nounderline abstract_t">Yavuz MN, Yavuz AA, Aydin F, et al. The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study. Int J Radiat Oncol Biol Phys 2002; 54:195.</a></li><li><a class="nounderline abstract_t">Topkan E, Karaoglu A. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma. Oncology 2006; 71:354.</a></li><li><a class="nounderline abstract_t">Muecke R, Schomburg L, Glatzel M, et al. Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology. Int J Radiat Oncol Biol Phys 2010; 78:828.</a></li><li><a class="nounderline abstract_t">Liu MM, Li ST, Shu Y, Zhan HQ. Probiotics for prevention of radiation-induced diarrhea: A meta-analysis of randomized controlled trials. PLoS One 2017; 12:e0178870.</a></li><li><a class="nounderline abstract_t">Gandhi AK, Sharma DN, Rath GK, et al. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study. Int J Radiat Oncol Biol Phys 2013; 87:542.</a></li><li><a class="nounderline abstract_t">Vistad I, Kristensen GB, Fosså SD, et al. Intestinal malabsorption in long-term survivors of cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2009; 73:1141.</a></li><li><a class="nounderline abstract_t">Snijders-Keilholz A, Griffioen G, Davelaar J, et al. Vitamin B12 malabsorption after irradiation for gynaecological tumours. Anticancer Res 1993; 13:1877.</a></li><li><a class="nounderline abstract_t">Schreurs WH, Odink J, Egger RJ, et al. The influence of radiotherapy and chemotherapy on the vitamin status of cancer patients. Int J Vitam Nutr Res 1985; 55:425.</a></li><li><a class="nounderline abstract_t">Georg P, Boni A, Ghabuous A, et al. Time course of late rectal- and urinary bladder side effects after MRI-guided adaptive brachytherapy for cervical cancer. Strahlenther Onkol 2013; 189:535.</a></li><li><a class="nounderline abstract_t">Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004; 22:872.</a></li><li><a class="nounderline abstract_t">Charra-Brunaud C, Harter V, Delannes M, et al. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. Radiother Oncol 2012; 103:305.</a></li><li><a class="nounderline abstract_t">Mazeron R, Fokdal LU, Kirchheiner K, et al. Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study. Radiother Oncol 2016; 120:412.</a></li><li><a class="nounderline abstract_t">Kochhar R, Patel F, Dhar A, et al. Radiation-induced proctosigmoiditis. Prospective, randomized, double-blind controlled trial of oral sulfasalazine plus rectal steroids versus rectal sucralfate. Dig Dis Sci 1991; 36:103.</a></li><li><a class="nounderline abstract_t">Denton A, Forbes A, Andreyev J, Maher EJ. Non surgical interventions for late radiation proctitis in patients who have received radical radiotherapy to the pelvis. Cochrane Database Syst Rev 2002; :CD003455.</a></li><li><a class="nounderline abstract_t">Feldmeier JJ, Hampson NB. A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: an evidence based approach. Undersea Hyperb Med 2002; 29:4.</a></li><li><a class="nounderline abstract_t">Glover M, Smerdon GR, Andreyev HJ, et al. Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial. Lancet Oncol 2016; 17:224.</a></li><li><a class="nounderline abstract_t">Kaassis M, Oberti E, Burtin P, Boyer J. Argon plasma coagulation for the treatment of hemorrhagic radiation proctitis. Endoscopy 2000; 32:673.</a></li><li><a class="nounderline abstract_t">Yeoh E, Tam W, Schoeman M, et al. Argon plasma coagulation therapy versus topical formalin for intractable rectal bleeding and anorectal dysfunction after radiation therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2013; 87:954.</a></li><li><a class="nounderline abstract_t">Talley NA, Chen F, King D, et al. Short-chain fatty acids in the treatment of radiation proctitis: a randomized, double-blind, placebo-controlled, cross-over pilot trial. Dis Colon Rectum 1997; 40:1046.</a></li><li><a class="nounderline abstract_t">Flay LD, Matthews JH. The effects of radiotherapy and surgery on the sexual function of women treated for cervical cancer. Int J Radiat Oncol Biol Phys 1995; 31:399.</a></li><li><a class="nounderline abstract_t">Townamchai K, Lee L, Viswanathan AN. A novel low dose fractionation regimen for adjuvant vaginal brachytherapy in early stage endometrioid endometrial cancer. Gynecol Oncol 2012; 127:351.</a></li><li><a class="nounderline abstract_t">Ahlström CG. [The conception of cancer in times of old; a survey with special attention to Sweden]. Sydsven Medicinhist Sallsk Arsskr 1980; :10.</a></li><li><a class="nounderline abstract_t">Denton AS, Maher EJ. Interventions for the physical aspects of sexual dysfunction in women following pelvic radiotherapy. Cochrane Database Syst Rev 2003; :CD003750.</a></li><li><a class="nounderline abstract_t">Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1995; 32:1289.</a></li><li><a class="nounderline abstract_t">Williams JA Jr, Clarke D, Dennis WA, et al. The treatment of pelvic soft tissue radiation necrosis with hyperbaric oxygen. Am J Obstet Gynecol 1992; 167:412.</a></li><li><a class="nounderline abstract_t">Safra T, Gutman G, Fishlev G, et al. Improved quality of life with hyperbaric oxygen therapy in patients with persistent pelvic radiation-induced toxicity. Clin Oncol (R Coll Radiol) 2008; 20:284.</a></li><li><a class="nounderline abstract_t">Dion MW, Hussey DH, Doornbos JF, et al. Preliminary results of a pilot study of pentoxifylline in the treatment of late radiation soft tissue necrosis. Int J Radiat Oncol Biol Phys 1990; 19:401.</a></li><li><a class="nounderline abstract_t">Kirchheiner K, Nout RA, Lindegaard JC, et al. Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. Radiother Oncol 2016; 118:160.</a></li><li><a class="nounderline abstract_t">Vistad I, Cvancarova M, Fosså SD, Kristensen GB. Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients? Int J Radiat Oncol Biol Phys 2008; 71:1335.</a></li><li><a class="nounderline abstract_t">Pitkin RM, VanVoorhis LW. Postirradiation vaginitis. An evaluation of prophylaxis with topical estrogen. Radiology 1971; 99:417.</a></li><li><a class="nounderline abstract_t">Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy. Cochrane Database Syst Rev 2010; :CD007291.</a></li><li><a class="nounderline abstract_t">Decruze SB, Guthrie D, Magnani R. Prevention of vaginal stenosis in patients following vaginal brachytherapy. Clin Oncol (R Coll Radiol) 1999; 11:46.</a></li><li><a class="nounderline abstract_t">Bruner DW, Lanciano R, Keegan M, et al. Vaginal stenosis and sexual function following intracavitary radiation for the treatment of cervical and endometrial carcinoma. Int J Radiat Oncol Biol Phys 1993; 27:825.</a></li><li><a class="nounderline abstract_t">Robinson JW, Faris PD, Scott CB. Psychoeducational group increases vaginal dilation for younger women and reduces sexual fears for women of all ages with gynecological carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 1999; 44:497.</a></li><li><a class="nounderline abstract_t">Sobotkowski J, Markowska J, Fijuth J, Pietraszek A. Preliminary results of mitomycin C local application as post-treatment prevention of vaginal radiation-induced morbidity in women with cervical cancer. Eur J Gynaecol Oncol 2006; 27:356.</a></li><li><a class="nounderline abstract_t">Betalli P, De Corti F, Minucci D, et al. Successful topical treatment with mitomycin-C in a female with post-brachytherapy vaginal stricture. Pediatr Blood Cancer 2008; 51:550.</a></li><li><a class="nounderline abstract_t">Moore KN, Gold MA, McMeekin DS, Zorn KK. Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma. Gynecol Oncol 2007; 106:498.</a></li><li><a class="nounderline abstract_t">Wallace WH, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005; 62:738.</a></li><li><a class="nounderline abstract_t">Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod 2003; 18:117.</a></li><li><a class="nounderline abstract_t">Bisharah M, Tulandi T. Laparoscopic preservation of ovarian function: an underused procedure. Am J Obstet Gynecol 2003; 188:367.</a></li><li><a class="nounderline abstract_t">Morice P, Castaigne D, Haie-Meder C, et al. Laparoscopic ovarian transposition for pelvic malignancies: indications and functional outcomes. Fertil Steril 1998; 70:956.</a></li><li><a class="nounderline abstract_t">Morice P, Haie-Meder C, Pautier P, et al. Ovarian metastasis on transposed ovary in patients treated for squamous cell carcinoma of the uterine cervix: report of two cases and surgical implications. Gynecol Oncol 2001; 83:605.</a></li><li><a class="nounderline abstract_t">Baxter NN, Habermann EB, Tepper JE, et al. Risk of pelvic fractures in older women following pelvic irradiation. JAMA 2005; 294:2587.</a></li><li><a class="nounderline abstract_t">Ikushima H, Osaki K, Furutani S, et al. Pelvic bone complications following radiation therapy of gynecologic malignancies: clinical evaluation of radiation-induced pelvic insufficiency fractures. Gynecol Oncol 2006; 103:1100.</a></li><li><a class="nounderline abstract_t">Robins CJ, Luten AG. Sociotropy and autonomy: differential patterns of clinical presentation in unipolar depression. J Abnorm Psychol 1991; 100:74.</a></li><li><a class="nounderline abstract_t">Oh D, Huh SJ, Nam H, et al. Pelvic insufficiency fracture after pelvic radiotherapy for cervical cancer: analysis of risk factors. Int J Radiat Oncol Biol Phys 2008; 70:1183.</a></li><li><a class="nounderline abstract_t">Bliss P, Parsons CA, Blake PR. Incidence and possible aetiological factors in the development of pelvic insufficiency fractures following radical radiotherapy. Br J Radiol 1996; 69:548.</a></li><li><a class="nounderline abstract_t">Razavian N, Laucis A, Sun Y, et al. Radiation-Induced Insufficiency Fractures After Pelvic Irradiation for Gynecologic Malignancies: A Systematic Review. Int J Radiat Oncol Biol Phys 2020; 108:620.</a></li><li><a class="nounderline abstract_t">Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18:1606.</a></li><li><a class="nounderline abstract_t">Klopp AH, Moughan J, Portelance L, et al. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys 2013; 86:83.</a></li><li><a class="nounderline abstract_t">Rose BS, Aydogan B, Liang Y, et al. Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2011; 79:800.</a></li><li><a class="nounderline abstract_t">Mell LK, Kochanski JD, Roeske JC, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66:1356.</a></li><li><a class="nounderline abstract_t">Georgiou A, Grigsby PW, Perez CA. Radiation induced lumbosacral plexopathy in gynecologic tumors: clinical findings and dosimetric analysis. Int J Radiat Oncol Biol Phys 1993; 26:479.</a></li><li><a class="nounderline abstract_t">Gothard L, Cornes P, Brooker S, et al. Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy. Radiother Oncol 2005; 75:334.</a></li></ol></div><div id="topicVersionRevision">Topic 90926 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15305397" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part II--carcinoma of the endometrium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15305396" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part I--malignancies of the cervix, ovary, vagina and vulva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12202666" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18035210" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Radiotherapy in setting of collagen vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10705022" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10386640" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Rectal cancer and inflammatory bowel disease: natural history and implications for radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11567821" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acute and late radiotherapy toxicity in patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4843305" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Radiation and small bowel complications in cervical carcinoma therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4842260" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bladder or rectal injury following radiation therapy for cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12885450" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Factors determining acute normal tissue reactions during postoperative radiotherapy in endometrial cancer: analysis of 317 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20171505" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Radiation dose-volume effects of the urinary bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29989857" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32073955" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7713787" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1172868" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Editorial: The humanization of medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21444867" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10202164" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21345618" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32828387" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evidence-Based Dose Planning Aims and Dose Prescription in Image-Guided Brachytherapy Combined With Radiochemotherapy in Locally Advanced Cervical Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29559282" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Risk of Late Urinary Complications Following Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: Refining Bladder Dose-Volume Parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6722748" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Radiation therapy alone in the treatment of carcinoma of the uterine cervix. II. Analysis of complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15476520" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The management of haemorrhagic cystitis with sodium pentosan polysulphate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24035333" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hyperbaric oxygen treatment in radiation-induced cystitis and proctitis: a prospective cohort study on patient-perceived quality of recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31537473" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19546404" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11510566" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effects of radiation damage on intestinal morphology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20171503" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Radiation dose-volume effects in the stomach and small bowel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11728684" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20206777" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10202166" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17394944" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23159818" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24630537" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Impact of post operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: results of the phase II RTCMIENDOMETRE French multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34506246" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11072942" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Topical butyrate for acute radiation proctitis: randomised, crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19107351" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Sodium butyrate enemas in the treatment of acute radiation-induced proctitis in patients with prostate cancer and the impact on late proctitis. A prospective evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31286233" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32786044" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16586122" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Amifostine in the management of radiation-induced and chemo-induced mucositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15592688" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9406364" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16849762" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12182992" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17873499" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20133068" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28575095" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Probiotics for prevention of radiation-induced diarrhea: A meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24074927" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18760883" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Intestinal malabsorption in long-term survivors of cervical cancer treated with radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8267396" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Vitamin B12 malabsorption after irradiation for gynaecological tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4086213" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The influence of radiotherapy and chemotherapy on the vitamin status of cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23703404" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Time course of late rectal- and urinary bladder side effects after MRI-guided adaptive brachytherapy for cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14990643" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22633469" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27396811" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1670631" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Radiation-induced proctosigmoiditis. Prospective, randomized, double-blind controlled trial of oral sulfasalazine plus rectal steroids versus rectal sucralfate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11869662" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Non surgical interventions for late radiation proctitis in patients who have received radical radiotherapy to the pelvis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12507182" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: an evidence based approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26703894" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10989989" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Argon plasma coagulation for the treatment of hemorrhagic radiation proctitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24113059" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Argon plasma coagulation therapy versus topical formalin for intractable rectal bleeding and anorectal dysfunction after radiation therapy for prostate carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9293933" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Short-chain fatty acids in the treatment of radiation proctitis: a randomized, double-blind, placebo-controlled, cross-over pilot trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7836095" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The effects of radiotherapy and surgery on the sexual function of women treated for cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22850411" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A novel low dose fractionation regimen for adjuvant vaginal brachytherapy in early stage endometrioid endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11628684" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : [The conception of cancer in times of old; a survey with special attention to Sweden].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12535485" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Interventions for the physical aspects of sexual dysfunction in women following pelvic radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7635768" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1497044" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The treatment of pelvic soft tissue radiation necrosis with hyperbaric oxygen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18222656" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Improved quality of life with hyperbaric oxygen therapy in patients with persistent pelvic radiation-induced toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2394619" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Preliminary results of a pilot study of pentoxifylline in the treatment of late radiation soft tissue necrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26780997" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18355976" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5553582" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Postirradiation vaginitis. An evaluation of prophylaxis with topical estrogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20824858" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Vaginal dilator therapy for women receiving pelvic radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10194586" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Prevention of vaginal stenosis in patients following vaginal brachytherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8244811" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Vaginal stenosis and sexual function following intracavitary radiation for the treatment of cervical and endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10348277" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Psychoeducational group increases vaginal dilation for younger women and reduces sexual fears for women of all ages with gynecological carcinoma treated with radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17009625" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Preliminary results of mitomycin C local application as post-treatment prevention of vaginal radiation-induced morbidity in women with cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18506768" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Successful topical treatment with mitomycin-C in a female with post-brachytherapy vaginal stricture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17561235" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15936554" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Predicting age of ovarian failure after radiation to a field that includes the ovaries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12525451" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The radiosensitivity of the human oocyte.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12592241" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Laparoscopic preservation of ovarian function: an underused procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9806584" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Laparoscopic ovarian transposition for pelvic malignancies: indications and functional outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11733981" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Ovarian metastasis on transposed ovary in patients treated for squamous cell carcinoma of the uterine cervix: report of two cases and surgical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16304072" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Risk of pelvic fractures in older women following pelvic irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16919711" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pelvic bone complications following radiation therapy of gynecologic malignancies: clinical evaluation of radiation-induced pelvic insufficiency fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2005274" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Sociotropy and autonomy: differential patterns of clinical presentation in unipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919836" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Pelvic insufficiency fracture after pelvic radiotherapy for cervical cancer: analysis of risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8757658" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Incidence and possible aetiological factors in the development of pelvic insufficiency fractures following radical radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32442476" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Radiation-Induced Insufficiency Fractures After Pelvic Irradiation for Gynecologic Malignancies: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764420" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23582248" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20400238" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16757127" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8514543" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Radiation induced lumbosacral plexopathy in gynecologic tumors: clinical findings and dosimetric analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16086914" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
